Introduction {#s0001}
============

This review is focused on how the phosphorylation state of pocket proteins is maintained throughout the cell cycle and perturbed in response to signals that promote growth arrest via rapid dephosphorylation of pocket proteins. Because reactivation of pocket proteins by upregulation of CDK inhibitors has been extensively studied and been the epicenter of numerous excellent reviews, (reviewed in refs.[@cit0001]) this manuscript is centered on the role played by serine/threonine protein phosphatases and in particular PP2A.

Holoenzymes, Substrates and Other Factors in the Equilibrium that Determines the Phosphorylation State of Pocket Proteins {#s0002}
=========================================================================================================================

Pocket protein structure and function {#s0002-0001}
-------------------------------------

The cell cycle is negatively regulated by the retinoblastoma family of proteins, commonly designated "pocket proteins," which mediate transcriptional repression of many cell cycle genes. (reviewed in refs.[@cit0005]) The pocket protein family includes the pRB tumor suppressor protein and the 2 closely related paralog proteins p107 and p130 (also designated RBL1 and RBL2, respectively). The *RB* gene is named for the disease in which it was first found to be mutated.[@cit0008]

Pocket proteins consist of 5 major domains: the N- and C- terminal domains, 2 "pocket" domains designated "A" and "B," and a spacer region that links the 2 pocket domains. (reviewed in refs.[@cit0009]) The highest degree of homology among all 3 pocket proteins lies in the pocket domains, whereas the spacer and N-terminal domains are more divergent. p107 and p130 share ∼54% homology with each other, while pRB is only 25% homologous to p107 and p130 (reviewed in ref.[@cit0005]). Adenoviral E1A was the first viral oncoprotein found to bind pRB,[@cit0013] and 2 conserved regions containing amino acids ∼40-70 and ∼121-139 were found to be required for pRB binding.[@cit0013] Sequence alignments revealed that SV40 T-antigen and HPV E7 also contained these conserved motifs.[@cit0016] These 3 viral proteins all share one common motif- LXCXE- required to bind pocket proteins, which is also present in some Cyclins and other cellular proteins. Deletion of this motif rendered HPV E7 unable to bind pRB.[@cit0017] The pocket region of the pRB family is comprised of 2 domains, "A" and "B," that resemble cyclin folds (reviewed in refs.[@cit0005]). These folds form a structure that serves as a binding site for a majority of the proteins known to interact with pocket proteins, including Cyclins, E2Fs, histone deacetylases, and c-Myc, among others (reviewed in refs.[@cit0009]). p107 and p130 contain a Cyclin/CDK binding site in their spacer in addition to CDK inhibitory regions in their N-termini that inhibit Cyclin/CDK2 complexes.[@cit0020] In contrast, pRB does not contain a kinase inhibitory domain, and its Cyclin/CDK binding site is located at the C-terminus.[@cit0022]

The expression of pocket proteins is differentially regulated throughout the cell cycle. p130 is expressed highly in quiescent cells and is present at promoters of genes required for cell cycle exit. During G1, p130 is hyperphosphorylated to form 3, the slowest migrating hyperphosphorylated form of p130, which is quickly downregulated.[@cit0024] This is due to targeted degradation by the ubiquitin ligase SCF^Skp2^.[@cit0027] p107 is undetectable or expressed at low levels in quiescent cells, as its E2F dependent promoter is repressed in G0.[@cit0029] p107 is expressed starting in mid-G1 following mitogenic stimulation.[@cit0030] pRB levels increase slightly from G1 as it is also an E2F responsive gene, however, changes in pRB expression are not as dramatic as they are for p107 or p130 (reviewed in refs.[@cit0012]).

Pocket proteins are recruited to promoters when complexed with members of the E2F family. There are 2 main varieties of E2Fs that associate with pocket proteins: the "activator" E2Fs and the "repressor" E2Fs. The activator E2Fs- E2F1, E2F2, and E2F3a- are reported to primarily associate with pRB in G1[@cit0032] and are responsible for transcription of the E2F gene program from mid to late G1 through S phase when released from pocket proteins.[@cit0034] Phosphorylation by the coordinated action of Cyclin D/CDK4/6 and Cyclin E/CDK2 complexes in mid to late G1 dissociates pocket proteins from E2Fs allowing binding of positive transcription cofactors such as p300, CBP, P/CAF and other histone acetylases (reviewed in ref.[@cit0035]). Association of "activator" E2Fs (aE2Fs) with p107 and p130 has also been reported.[@cit0037] While these complexes are less abundant than pRB/aE2Fs complexes,[@cit0038] changes in the expression of both E2Fs and the hypophosphorylated forms of pocket proteins are likely to regulate their relative abundance. However, whether their function is different than that of pRB/aE2F complexes is not known.

p107 and p130 are preferential partners of E2F4 and E2F5, referred to as "repressor" E2Fs. These E2Fs are not found at gene promoters unless they are bound by pocket proteins.[@cit0033] Following Cyclin/CDK inactivation of p107 or p130 in mid to late-G1, E2F4 is exported to the cytoplasm,[@cit0040] where it remains until it binds hypophosphorylated p107 or p130 again, as cells exit mitosis and progress through G1 or exit the cell cycle into G0. At this point the newly formed E2F4/pocket protein complexes translocate to the nucleus to repress transcription of E2F-dependent genes.[@cit0034] Although not so exhaustively studied, E2F5 is believed to behave similarly in cells where it is expressed (reviewed in ref.[@cit0036]).

Thus, pocket proteins are negative regulators of the cell cycle. In their active- or hypophosphorylated- state, which normally occurs in quiescent cells or the G1 phase of the cell cycle, they are associated with E2F and DP transcription factor heterodimers and bound to the promoters of E2F dependent genes, which result in the active repression of cell cycle genes. Upon mitogenic stimulation, G1 and G1/S Cyclin/CDK complexes phosphorylate pocket proteins, resulting in their release from E2F/DP complexes. In the absence of pocket protein binding, activator E2Fs 1-3a become positive transcription factors or transactivators, allowing p300, CBP, P/CAF and other histone acetylases to bind, thus promoting cell cycle progression through the restriction point (reviewed in refs.[@cit0012]).

Pocket protein activity is determined by Cyclin/CDK complexes and Ser/Thr Protein Phosphatases throughout the cell cycle {#s0002-0002}
------------------------------------------------------------------------------------------------------------------------

pRB and p130 are inactivated by the coordinated action of Cyclin D/CDK4/6 and Cyclin E/CDK2 complexes. p107 appears to be mostly inactivated by Cyclin D/CDK4/6, but phosphorylation of certain residues by Cyclin E/CDK2 has been observed (reviewed in refs.[@cit0011]). Once phosphorylated, pRB, p107 and p130 remain in a hyperphosphorylated (inactive) state throughout the remainder of the cell cycle until late mitosis, where they are abruptly dephosphorylated coinciding with Cyclin/CDK inactivation in preparation for the next round of the cell cycle. More precisely, pRB was found to be rather rapidly dephosphorylated in anaphase following nocodazole block and release in various cell types, suggesting that a phosphatase was responsible. Treatment of late mitotic cell extracts with metal ion chelators revealed the dephosphorylation of pRB was not mediated by PP2B and/or PP2C, as they require calcium and magnesium for their catalytic activity, respectively. pRB dephosphorylation in the same extracts was sensitive to \>10 nM okadaic acid, which suggested PP1 was involved.[@cit0043] Around the same time, another laboratory identified the PP1α2 isoform as a pRB binding partner in a yeast 2-hybrid screen, and showed that the timing of the interaction of PP1α2 and pRB lasts from M phase to mid-G1, when cell cycle CDKs are inactive. Interestingly, it also was shown that PP1α2 cannot bind a pRB C-terminal deletion mutant.[@cit0044] From this evidence, a model emerged suggesting that from mid-G1 to mitosis, CDKs are "switched on," resulting in the inactivation of pocket proteins, until late mitosis, where the CDKs are "switched off." Conversely, PP1 is "switched on" in anaphase, leading to the reactivation of pocket proteins until early/mid-G1, when PP1 would be "switched off."[@cit0045] Although PP1 had been implicated in targeting pRB, it was not shown to interact with p107 or p130 at the time, and a later study showed that p107 only weakly bound to PP1α while p130 failed to bind.[@cit0047]

PP2A holoenzymes have been shown to interact with all 3 pocket proteins upon cellular stresses or extracellular signaling.[@cit0048] Subsequently, PP2A holoenzymes were hypothesized to mediate an equilibrium with CDKs that determines the phosphorylation state of all 3 pocket proteins during the cell cycle.[@cit0052] This idea arose from the observation that pocket proteins were rapidly dephosphorylated in asynchronous cells following treatments with cycloheximide or the pan CDK inhibitor flavopiridol, suggesting rapid dephosphorylation following CDK inhibition independently of cell cycle position. Treatment of cells with the phosphatase inhibitors calyculin A and okadaic acid at concentrations that preferentially inhibit PP2A rather than PP1 *in vivo* suggested the phosphatase responsible was PP2A. Consistently, expression of SV40 small t antigen, known to displace B subunits from the PP2A core enzyme, inhibited the dephosphorylation of p107 triggered by CDK inhibition. Finally, the catalytic subunit of PP2A was found to immunoprecipitate with p107 and p130 in lysates from serum starved T98G cells at different points upon re-stimulation with FBS, showing that PP2A targets pocket proteins throughout the cell cycle.[@cit0052] These observations started to shape a "dynamic equilibrium" model described in ([**Fig. 1**](#f0001){ref-type="fig"}), where PP2A holoenzymes modulate pocket protein activity throughout the cell cycle in coordination with inducible CDKs, while PP1 resets pRB specifically in mitosis (reviewed in ref.[@cit0042]). However, PP2A consists of a collection of trimeric holoenzymes that come in many "flavors" resulting from combination of its 3 subunits: the "C" catalytic subunit, the "A" scaffolding subunit and a "B" regulatory subunit. Hence, the nature of the PP2A holoenzyme targeting pocket proteins during the cell cycle was unknown because the B subunit(s) implicated had yet to be identified. Figure 1.A dynamic equilibrium between inducible CDKs and PP2A modulate the phosphorylation state of pocket proteins through the cell cycle. (**A**) Pocket proteins are active in their hypophosphorylated state. Pocket proteins are hypophosphorylated in early to mid G1 or in G0, when they are found associated with E2F/DP complexes and other proteins. Hypophosphorylated pocket proteins are also thought to bind transcription factors involved in differentiation (not shown). Pocket proteins are inactivated by CDK-dependent hyperphosphorylation. G1 Cyclin D1/CDKs start the process, which is coordinated with G1/S Cyclin E/CDK2 and maintained through S phase and mitosis by Cyclin A/CDK2 and Cyclin B/CDK1. PP2A and PP1 oppose the effects of CDKs. PP2A is active toward the 3 pocket proteins through the cell cycle and in quiescent cells, and this activity may be mediated by the cooperation of various trimeric PP2A holoenzymes (B(s)/PP2A) most prominently PP2A/B55α and PP2A/B55δ and perhaps PP2A/PR70 (see details in the text and 1B). This activity is regulated by a variety of signals and likely down-modulated in mitosis (see text for details). The hyperphosphorylation mediated by inducible CDKs, inactivates pocket proteins by disrupting/preventing their association with E2Fs, which mediates passage through the restriction point by triggering the expression of E2F-dependent (E2Fd) genes needed for DNA synthesis and, later, mitosis. When CDKs are inactivated late in mitosis (M~L~), B55/PP2A and in the case of pRB, PP1 abruptly dephosphorylate pocket proteins, resetting them to their active state (G1~E~, designates ealy G1). Arrows show the cell cycle activity span of the kinase or phosphatase with the same color. (**B**) B55α/PP2A appears to be one of the trimeric holoenzymes in equilibrium with CDKs through the cell cycle. This holoenzyme primarily targets p107 and p130 to a lesser extent. Since an interaction of this holoenzyme with pRB in chondrocytes has been detected, it is possible that it modulates all 3 pocket proteins, although likely with differential affinity. PR70/PP2A interacts with pRB in cells and with pRB and p130 *in vitro*. It remains to be determined if PR70/PP2A holoenzymes contribute to maintain the equilibrium with CDKs during the cell cycle or only target pRB (and perhaps the other pocket proteins) in response to certain stimuli (i.e., oxidative stress).

PP2A holoenzyme subunit composition and structure {#s0002-0003}
-------------------------------------------------

PP2A is an abundant serine/threonine phosphatase that is responsible for the dephosphorylation of a myriad of substrates: The A/C dimer is referred to as the "core enzyme;" when the core dimer is bound to a regulatory subunit it is referred to as a holoenzyme ([**Fig. 2**](#f0002){ref-type="fig"}). PP2A is involved in a vast number of cellular functions and some of its major targets include the pocket protein family, p53, the MAPK and AKT pathways and many mitotic substrates often phosphorylated by CDKs (reviewed in refs.[@cit0042]). Figure 2.Trimeric PP2A holoenzyme and core dimer composition. The cartoon depicts the 4 types of trimeric holoenzymes and the core dimer. All the B regulatory subunit genes in each family are listed. The crystal structure of the core dimer and the trimeric holoenzymes containing B (B55α), B' (B56γ) or B\" (PR70) have been solved (see text for details). The bending of the scaffold changes with each B subunit, and the bending is maximum with PR70. It is thought that the particular B/C interfaces create B-family specific pockets for substrates. The structure of the B\"'/PP2A holoenzymes has not ben solved (represented by a dashed B\"' subunit). B55α is a β-propeller with 7 blades and make less contacts with the catalytic subunit than B56γ. B56γ contains HEAT repeats like the scaffold. The PR70 structure is elongated and contains calcium binding sites, represented by green spheres. See text for additional details.

### PP2A/C- the catalytic subunit {#s0002-0003-0001}

There are 2 isoforms of PP2A/C, termed PP2A/Cα and PP2A/Cβ, with the former being more abundant. They are 98% identical, with most of the divergence in the N-terminus.[@cit0055] The knockout of the α isoform of the catalytic subunit is lethal around embryonic day 6, shortly after implantation.[@cit0056] The catalytic subunit contacts the scaffold subunit on its C-terminal HEAT repeats (see below). In contrast, the contacts that PP2A/C makes with B subunits are unique for each B-family.

The C-terminal tail of the catalytic subunit is highly conserved, and is required for the binding of B family subunits. Mutation and deletion of the 304-TPDYFL-309 tail prevents the regulatory B subunit (B55) from binding to the core enzyme.[@cit0057] The T304, Y307, and L309 residues can be modified by phosphorylation[@cit0058] or methylation[@cit0060] respectively. Phosphorylation of Y307 by tyrosine kinases including v-SRC and EGFR[@cit0058] and T304 inhibits phosphatase activity. Phosphorylation of these residues is increased in the presence of okadaic acid, suggesting PP2A autodephosphorylates.[@cit0058] Methylation of L309 is modulated by the methyltransferase LCMT-1,[@cit0060] the methylesterase PME-1[@cit0062] and PTPA.[@cit0064] Methylation of the catalytic subunit is believed to play a role in specific B subunit recruitment to the core enzyme.[@cit0059] For example, methylation of L309 was found to be necessary for the binding of the B55α subunit in cells, but not members of the B′, B″ and B″′ family.[@cit0059] Because it appears to be necessary for binding in cells but not *in vitro*,[@cit0071] these results may suggest that L309 methylation is not required for B subunit binding but it may enhance affinity, or alternatively, it may serve as a recruitment signal to a specific cellular location or for other cofactors needed for holoenzyme assembly (reviewed in ref.[@cit0072]).

### PP2A/A- the scaffold subunit {#s0002-0003-0002}

The "A" subunit of the PP2A holoenzyme, PP2A/A, also called PR65, serves as the scaffold for the regulatory and catalytic subunits. There are 2 isoforms, PP2A/Aα and PP2A/Aβ, which share 87% sequence identity.[@cit0073] The α isoform is expressed in most tissues, while the β isoform is enriched in the testis.[@cit0074] The scaffold subunit is structurally composed of a series of antiparallel α-helices known as HEAT (Huntington, elongation factor 3, PR65/A, TOR) repeats,[@cit0075] which give these proteins a horseshoe-like structure. The catalytic subunit makes contacts with the C-terminal HEAT repeats 11-15,[@cit0076] whereas the B subunit contacts the N-terminal repeats. Crystal structures of the B, B' and B\" families have revealed that although very structurally divergent, the B and B\" subunits contact HEAT repeats 1--7[@cit0077] and the B' subunits contact HEAT repeats 2--8.[@cit0076] The scaffolding subunit also demonstrates flexibility, as the HEAT repeats twist and shift to varying degrees upon binding of the regulatory and catalytic subunits (reviewed in ref.[@cit0072]).

### PP2A/B- the regulatory subunit {#s0002-0003-0003}

The B subunit is the major determinant in substrate specificity and subcellular localization. To date, 15 separate B subunits in 4 major families have been identified. Aside from the 4 known families of subunits, other cellular interactors and viral oncogenes such as SV40 small t and Adenovirus E4ORF4 can also associate with the core enzyme, resulting in over 200 biochemically distinct combinations (reviewed in ref.[@cit0080])([**Fig. 2**](#f0002){ref-type="fig"}).

The B family, also called PR55, B55, or *PPP2R2*, has 4 major isoforms, most commonly referred to as B55α, B55β, B55γ, and B55δ. The members of the B family are highly conserved; most of their structural differences lie in the N-terminus. B55α and B55δ are expressed in most tissues and are much more structurally similar to each other than B55β and B55γ, which are reported to be enriched in brain tissue (reviewed in ref.[@cit0053]). B family subunits have a β-propeller structure comprised of 7 blades, each formed by WD-40 repeats. The crystal structure of the PP2A holoenzyme containing the B55α subunit[@cit0077] demonstrates that B-family subunits make multiple contacts with the first 7 HEAT repeats in the A scaffolding subunit but very little contact with the catalytic subunit, which is bound to the C-terminal HEAT repeats of the scaffold.[@cit0081] Given the high similarities within the members of this family, it is likely the other isoforms contact the core enzyme in a similar fashion. On the exposed top face of the B55α subunit is an acidic "groove" that is believed to serve as the substrate binding site, and mutation of specific residues in this area prevent the dephosphorylation of Tau, a known substrate of B55α, *in vitro*.[@cit0077] Additionally, one of these mutants, B55α-D197K, is also unable to bind p107, another substrate of B55α,[@cit0082] and is also noticeably deficient in binding the core enzyme. Of note, other sites that are important for B55α to mediate dephosphorylation of Tau have little effect on B55α/p107 binding, suggesting that different combinations of residues within the charged top of B55α determine specific binding to a variety of unrelated substrates.[@cit0082]

The B', also called the PR61, B56 or *PPP2R5* family is encoded by 5 genes, some with multiple isoforms, for a total of 10 known products.[@cit0083] The crystal structure of B56γ revealed that B56 family members are composed of HEAT repeats, a structure similar to that of the scaffold subunit. B56γ interacts with the N-terminal HEAT repeats of the scaffolding subunit and lie almost perpendicularly across the N-terminus. However, unlike the B55α subunit, B56γ makes substantial contacts with the catalytic subunit.[@cit0076] It is believed that the substrate binding site of B56 family members also lies on the top side of the subunit, as the B56γ subunit also has a highly acidic concave groove.[@cit0076] At least one residue, E153, which is conserved in all B56 family members, when mutated in B56β, remained bound to the core enzyme but failed to dephosphorylate tyrosine hydroxylase, a known substrate.[@cit0084]

The B″, or PR72/*PPP2R3* family of subunits, has 3 known members- PR130/PR72, PR70/PR48 and G5PR. This particular family is unique in that they possesses Ca^2+^-binding EF-hand motifs, as their binding to the core enzyme is calcium dependent.[@cit0085] The PR72 and PR130 subunits are differentially transcribed from the same gene by 2 different promoters.[@cit0086] PR48 was identified in a yeast 2-hybrid screen using the licensing factor CDC6 as bait[@cit0087] and it was later found that PR70 is the full length version of this subunit. Very recently, the crystal structures of the holoenzyme harboring the PR70 subunit and the monomeric PR72 subunit have been solved.[@cit0078] Like the holoenzymes containing the B and B' subunits, PR70 also contacts the N-terminal HEAT repeats of the scaffold subunit. The binding of PR70 to the scaffold subunit has a unique effect; it "compacts" the scaffold, yet at the same time increases the height of both the scaffold and the holoenzyme. Aside from the EF motifs, PR70 has a hydrophobic N-terminus and a C-terminus. The C terminus makes contact with the catalytic subunit, and since it was previously shown that residues 440-575 contact CDC6,[@cit0088] it is proposed that the C-terminus is the substrate binding site,[@cit0078] which is different than that of members of the B and B' families, which as mentioned earlier, are believed to use an acidic top surface to contact substrates. Another member of this family, PR59, was identified in murine cells and found to bind p107,[@cit0049] yet this subunit has not been identified in humans. PR59 is 56% identical to PR72, however, PR72 is not known to bind pocket proteins. PR70, on the other hand, which is known to bind pRB,[@cit0089] has not been identified in mice. Considering PR59 and PR70 both bind pocket proteins, they may share related roles (reviewed in ref.[@cit0042]).

The B″′ family has 3 known members: striatin, S/G2 nuclear autoantigen (SG2NA) and zinedin. The B″′ family are structurally composed of caveolin and calcium-binding domains in their N-termini, which flank a coiled-coil domain. The C-termini are composed of WD-40 repeats. They are believed to be a unique subunit family as PP2A/A and PP2A/C were the only proteins found associated with them with no other B subunits present.[@cit0090] Later, other interactors were found associated within the PP2A complex, including kinases among others, suggesting that the phosphatase activity is not the only role of this complex. This complex was named STRIPAK.[@cit0091] STRIPAK complexes have been implicated in vast number of cellular processes, including cell cycle control, cell signaling and migration among others (reviewed in ref.[@cit0092]).

In sum, crystallography studies have revealed that subunits of the B, B′ and B″ families differ in the way they contact the catalytic subunit. B family subunits make little contact with the C subunit with its interaction being limited to Van der Waals contacts.[@cit0077] The B′ and B″ family members make significantly more contact. The B56γ subunit interacts with PP2A/Cα at 2 major interfaces- the HEAT repeats 6--8 of B56γ and the α5 region of PP2A/Cα and in a surface groove at the interface between PP2A/Aα and B56γ, mainly with hydrogen bonds.[@cit0079] The PR70 subunit of the B″ family makes 2 main contacts with PP2A/C near its active site and also in a shallow groove in a different region, and these interactions are mainly hydrogen bonds and salt bridges.[@cit0078] Altogether, the B/C interactions seem to facilitate the formation of distinct pockets to bring phosphorylated substrates in position for catalysis. Hence, the considerable diversity of B family subunits allows the sharing of similar scaffold/catalytic core dimers to target a large variety of unrelated substrates belonging to multiple cellular pathways. Moreover, the B subunits appear also to be responsible for relaying intra and extracellular signals in a variety of pathways. Perhaps better understood is the mitogen-induced recruitment of B55 subunits to PP2A/C-PP2A/A core dimers preassembled with inactive Raf1 and KSR1, which are sequestered by 14-3-3 proteins in the absence of mitogenic input.[@cit0093]

Cell Cycle and Signal Activated Dephosphorylation of Pocket Proteins by PP2A {#s0003}
============================================================================

A dynamic CDK/PP2A equilibrium during the cell cycle {#s0003-0001}
----------------------------------------------------

Having shown that PP2A was in a dynamic equilibrium with CDKs that determines the phosphorylation state of pocket proteins during the cell cycle,[@cit0052] it was necessary to identify the specific B subunit(s) of this PP2A holoenzyme. Using GST pull down assays, it was shown that the B55α subunit binds p107 and p130 to a lesser extent, but did not bind pRB robustly in U-2 OS cell lysates.[@cit0082] Of note, the B55α/PP2A holoenzyme was pulled down by GST-p107 from whole cell lysates or from a preparation of purified holoenzyme, indicating that no other proteins are required for complex formation. Consistent with these data, endogenous p107 and B55α were found to co-immunoprecipitate. The spacer region of p107, with the help of the C-terminus, was found to mediate the interaction between B55α and by extension the PP2A holoenzyme. In contrast, the PP1 binding site in pRB resides in the C-terminus and overlaps with CDK binding sites.[@cit0094] Forced modulation of B55α protein levels affected the phosphorylation status of p107, with limited ectopic expression resulting in hypophosphorylation, and B55α knockdown in hyperphosphorylation.[@cit0082] These findings were also consistent with the ability of the purified B55α/PP2A holoenzyme to dephosphorylate p107 *in vitro*. Importantly, SV40 small t antigen, which disrupts the binding of B55α to the PP2A core dimer in cells, does not disrupt the interaction between B55α and p107,[@cit0082] reinforcing the idea that B55α mediates the interaction between p107 and the holoenzyme. Altogether, these results suggested a more complete PP2A/CDK equilibrium model, as depicted in [**Figure 1A and B**](#f0001){ref-type="fig"}. In G0 or early G1, CDK activity is low and pocket proteins are hypophosphorylated. Upon mitogenic stimulation, activated G1 and G1/S CDKs hyperphosphorylate pocket proteins leading to their inactivation, which allows the cell cycle to proceed. PP2A has the potential to dephosphorylate pocket proteins in all phases of the cell cycle.[@cit0052] PR70 holoenzymes target Prb,[@cit0082] and B55α holoenzymes target p107 and p130.[@cit0082] In mitosis, PP1 is also believed to be involved in resetting pRB to its active state.[@cit0043] In this model, CDKs are depicted as the inducible enzymes that determine the phosphorylation state of pocket proteins in equilibrium with PP2A holoenzymes. However, it remained unclear if PP2A could be independently upregulated in this equilibrium by cellular signals to cause rapid cell cycle exit in the absence of CDK inactivation and if this is mediated by regulation of specific B subunits.

PP2A targeting pocket proteins in response to signals and stresses {#s0003-0002}
------------------------------------------------------------------

A handful of studies have described rapid PP2A mediated dephosphorylation of pocket proteins in response to extracellular signals and stresses, suggesting that PP2A activity may be regulated to target pocket proteins even if CDK activity is not concomitantly affected by these signals ([**Table 1**](#t0001){ref-type="table"}). p107 was reported to be rapidly dephosphorylated in response to UV irradiation of NIH-3T3 fibroblasts, which transiently arrested in the G1 phase of the cell cycle 90 minutes post-exposure.[@cit0051] EMSA assays followed by western blotting showed there was an accumulation of complexed E2F after treatment, and p107 was the predominant pocket protein present. p107 dephosphorylation was blocked in cells pre-treated with concentrations of okadaic acid specific to PP2A, implicating it as the phosphatase responsible. The exact B subunit responsible for the UV induced dephosphorylation of p107 was not identified, but overexpression of PR72, a subunit known to not bind p107, blocked this effect, presumably acting as a dominant negative via sequestration of the PP2A core dimer.[@cit0051] At the time, a novel subunit designated PR59 was found to target p107,[@cit0049] but was never directly implicated in this process. Table 1.PP2 A holoenzymes targeting pocket proteins during the cell cycle and in response to signalsSignalPocket ProteinB SubunitReferenceH~2~O~2~/Oxidative StresspRB, p107, p130PR70 (PR48), NDMagenta et al., 2008, Cicchillitti et al., 2003UV Irradiationp107NDVoorhoeve et al., 1999bAll-*trans*-Retinoic Acid (Ovarian cancer cells)p130NDPurev et al., 2006Ionizing RadiationpRBNDAvni et al., 2003FGF (chondrocytes)p107B55α (B55δ minor?)Kurimchak et al., 2013, Kolupaeva et al., 2013Cell Cycle   All phasesp107, p130, pRB?B55αGarriga et al., 2004, Jayadeva et al., 2010, Kurimchak et al., 2013 pRB, p130PR70?Jayadeva et al., 2010Mitosis/Early G1pRBPP1α2 + CDK inhibition PP1 + CDK inhibitionDurfee et al., 1993, Ludlow et al., 1993 pRb, p107, p130B55α/B55δ (likely) + CDK inhibitionAlthough not specifically tested, B55α-δ/PP2A holoenzymes dephosphorylate CDK substrates (reviewed in Kurimchak and Graña, 2012)

Oxidative stress is another mechanism that triggers PP2A dependent dephosphorylation of pocket proteins.[@cit0048] Treatment of HUVEC (human umbilical vein endothelial cells) with H~2~O~2~ results in dephosphorylation of all 3 pocket proteins within 30 minutes. This effect does not result in the modulation of Cyclin and CDK activity. The H~2~O~2~-dependent dephosphorylation of pocket proteins was prevented by okadaic acid at concentrations selective for inhibition of PP2A, and also by the expression of the SV40 small t antigen, which displaces B subunits from the PP2A core dimer.[@cit0048] Subsequently, PR70 was found to associate with pRB in U2-OS and HUVEC cells.[@cit0089] Overexpression of PR70 was sufficient to increase the levels of hypophosphorylated pRB in the absence of H~2~O~2~. PR70 shRNA prevented H~2~O~2~-dependent pRB dephosphorylation and DNA synthesis inhibition in HUVEC cells. Additionally, PR70 EF-hand motifs were found to be important for binding the PP2A core dimer and treatment with an intracellular calcium chelator prevented the dephosphorylation of pRB induced by H~2~O~2~, indicating that the dephosphorylation of pRB by PP2A/PR70 holoenzymes is calcium dependent.[@cit0089] Although it was previously shown that all 3 pocket proteins were sensitive to H~2~O~2~ induced dephosphorylation,[@cit0048] the particular subunits targeting p107 and p130 were not investigated in this study.

PP2A has also been shown to interact with p130 in ovarian carcinoma cells treated with all-*trans*-retinoic acid (ATRA). ATRA induces upregulation of PP2A activity along with the stabilization of p130 and G1 arrest.[@cit0050] p130 bound the catalytic subunit of PP2A, and this interaction was dependent on the intact nuclear localization signals on the C-terminus of p130.[@cit0095] Two specific serine and threonine residues (S1080 and T1097), which lie adjacent to the nuclear localization signals, were specifically found to be targeted by PP2A. Interestingly, importin α binds p130 at this region when these 2 residues are dephosphorylated, resulting in the translocation of p130 to the nucleus, which is followed by cell cycle arrest.[@cit0096] No B subunit was implicated in this process, yet since it is known that p130 can be targeted by both B55α and PR70, it is conceivable that one of these B subunits is implicated in the process.[@cit0082]

Although not directly investigated, another potential crosstalk between a pocket protein and PP2A is likely to occur in epithelial cells treated with TGF-β, where hypophosphorylated p107 associates with Smads, which are transcriptional regulators induced by TGF-β. Smad3 complexes with E2F4/5, DP1, and p107 in the cytoplasm, and upon TGF-β stimulation, this complex interacts with Smad4, translocates to the nucleus and binds to an adjacent Smad/E2F consensus site at the c-*MYC* promoter, repressing its transcription and resulting in cell cycle exit.[@cit0097] PP2A was not implicated in this process, however the B55α holoenzyme is known to be phosphorylated by the TGF-β type 1 receptor,[@cit0098] so it is possible it could target the holoenzyme to keep p107 hypophosphorylated. Indeed, Smads themselves are targeted by PP2A upon TGF-β/BMP stimulation. The PP2A/B55β holoenzyme was found to dephosphorylate BMPRII, ultimately leading to the same holoenzyme dephosphorylating Smads in their linker region, resulting in Smad complex nuclear translocation.[@cit0099]

PP2A and pocket proteins in development {#s0003-0003}
---------------------------------------

Perhaps best understood at this point are the PP2A-dependent signaling events leading to rapid dephosphorylation and activation of p107 in response to FGF1 stimulation in chondrocytes, which is associated with chondrocyte maturation and G1 arrest. These events are thought to be critical for endochondral bone formation and are mediated by FGF through the FGFR3 receptor.

The rapid activation of p107 by PP2A in chondrocytes following FGF stimulation is particularly intriguing for 2 reasons: (1) p130 and pRB are not dephosphorylated until several hours later,[@cit0100] and (2) chondrocytes require p107 and p130 for FGF-induced cell cycle exit[@cit0101] and for endochondral bone formation *in vivo*.[@cit0102] Therefore, it is of great interest to understand the mechanisms of PP2A activation toward p107 and its consequences. Kolupaeva et al. reported that the PP2A/p107 interaction that mediated p107 dephosphorylation and growth arrest were sensitive to the expression of SV40 st antigen and Adenovirus E4ORF4 proteins in Rat Chondrosarcoma (RCS) cells, which suggested that the holoenzyme implicated was defined by a B subunit of the B or B′ family.[@cit0100] On the other hand, B55α had been identified as the major B subunit targeting p107,[@cit0082] which met these characteristics. Thus, studies followed to identify the composition of the PP2A holoenzyme regulated by FGF in chondrocytes. However, before these studies are discussed it is important to review the crucial role of p107 and p130 in endochondral bone formation, which was first revealed via targeted inactivation of p107 and p130 in mice[@cit0102] and its link to FGF signaling.[@cit0103]

Mice that are p107−/− or p130−/− do not have early morbidity issues and develop normally.[@cit0102] When p107 −/+ and p130 −/+ mice were crossed, no live p107/p130 double knockouts were found at birth, and the dead neonates were detected below the Mendelian ratio, however, double knockout embryos were found alive at 18 days in Mendelian frequencies.[@cit0102] These embryos were ∼30% smaller than their littermates and had drastically shortened limbs. When stained with dyes to specifically detect cartilage or bone, the double knockout mice were found to have smaller rib cages and displayed less bone in the long bones of their limbs than control littermates. Consistently, chondrocyte density was doubled in the epiphyseal centers of the p107−/−;p130−/− mice as a result of increased chondrocyte proliferation, suggesting p107 and p130 specifically play a role in restricting chondrocyte proliferation in epiphyseal centers.[@cit0102] Significantly, the phenotype of the p107/p130 double knockout mice resembles that of achondroplasia, which is the most common form of dwarfism, as its most striking feature is the failure of long bone formation in the limbs. Achondroplasia in humans results from mutation of FGFR3 that render it constitutively active in the absence of FGF ligand (reviewed in ref.[@cit0105]). Endochondral bone formation is dependent on the proliferation, maturation, growth arrest, and eventual apoptosis of chondrocytes. This process begins with cartilage formation in the perichondrium, which is eventually replaced by bone. Mesenchymal cells condense and differentiate into 2 subspecies of proliferating chondrocytes, called low- and high- proliferating chondrocytes, which expand in different locations in the perichondrial space. Low proliferating chondrocytes are located toward the distal ends, whereas high-proliferating chondrocytes are organized in columns in the center. Proliferating chondrocytes exit the cell cycle and differentiate (or mature) into pre-hypertrophic and hypertrophic chondrocytes. The expansion of this population of cells is critical in skeletal elongation as it increases the length of what will eventually become the long bones of the limbs. These cells finally undergo apoptosis and are eventually replaced by trabecular bone (reviewed in ref.[@cit0106]).

Rat Chrondrosarcoma cells (RCS cells), a chondrocyte-like cell line that expresses FGFR3,[@cit0107] have extensively been used as a cellular model system to study the signaling events initiated by FGF that lead to chondrocyte maturation and cell cycle arrest. Treatment of RCS cells with FGF1 results in the autophosphorylation of FGFR3 and activated downstream targets such Phospholipase Cγ, AKT, ERK and p38 MAP kinases, but also resulted in unexpected growth inhibition, which was also observed in primary mouse chondrocyte cultures. Pharmacological inhibition of MEK and p38 MAPK inhibited growth arrest, possibly implicating these pathways in this process.[@cit0108] Inactivation of the AKT pathway may also play a role in FGF mediated RCS arrest, as FGF2 treatment leads to a gradual reduction in AKT activity, and expression of a constitutively active AKT mutant (myr-AKT) partially inhibits growth arrest.[@cit0110] Cells expressing myr-AKT were deficient in accumulating p130 upon arrest and retained some Cyclin E/CDK2 activity. However, expression of myr-AKT does not affect the expression of maturation genes induced by FGF treatment.[@cit0110]

The role of pocket proteins was also studied using RCS cells, where FGF1 treatment lead to dephosphorylation of all 3 pocket proteins and growth arrest that could be blocked by the expression of Adenovirus E1A or Large T antigen.[@cit0100] Importantly, RCS cells expressing a Large T mutant that is capable of binding pRB but not p107 or p130 were able to undergo growth arrest similarly to the parental cells, in complete agreement with the findings in mice, where compound inactivation of p107/p130 but not pRB result in defects in endochondral bone formation.[@cit0102] Furthermore, micromass chondrocyte cultures that were null for p107 and/or p130 were insensitive to FGF induced cell cycle arrest, while pRB null cultures behaved as the wild type, confirming the importance of p107 and/or p130 and the dispensability of pRB in this process. Of note, the p107 −/+; p130−/− micromass cultures did remain slightly responsive to FGF, suggesting p107 may play a more prominent role.[@cit0103]

On the other hand, endogenous CDK inhibitors have also been implicated in the cell cycle arrest induced by FGF in chondrocytes in both RCS cells and in endochondral bone formation in mice. In both systems, increased expression of CKIs is linked to pocket proteins. In this regard, mice with p107 ablation and knockin of an allele of p27 deficient in CDK binding (p27^D51/D5151/D51^) exhibit similar defects in endochondral bone formation as those seen in p107/p130 double knockout mice, although the phenotype is not as severe.[@cit0111] These mice exhibit elevated chondrocyte proliferation and shorter long bones. Thus, if p130 and p27 inactivation are interchangeable in a p107 null background, they may be involved in the same pathway in chondrocyte maturation.[@cit0111] Moreover, null mice for the CDK inhibitor p57 also exhibit defects in endochondral bone formation, suggesting that this CKI might be an upstream regulator of p107 and p130/p27 in chondrocytes.[@cit0112]

In RCS cells, p21 is upregulated in response to FGF1 stimulation and peaks coinciding with dephosphorylation of pRB (that occurs concomitantly to that of p130), several hours after p107 dephosphorylation. Thus, p21 upregulation, which results in Cyclin E/CDK2 inactivation,[@cit0113] may activate p130, while the activation of p107 is caused earlier by PP2A.[@cit0100] Consistently, overexpression of Cyclin D/CDK4 complexes block the dephosphorylation of p107 by FGF1 as well as the G1 cell cycle arrest that results from FGF treatment.[@cit0100]

FGF1 stimulates rapid p107 dephosphorylation by the PP2A/B55α holoenzyme in RCS cells. {#s0004}
======================================================================================

FGF1 stimulates a transient p107-PP2A/B55α holoenzyme interaction in chondrocytes {#s0004-0001}
---------------------------------------------------------------------------------

Therefore, a critical step in undestanding activation of p107 was the identification of the B regulatory subunit responsive to FGF1 stimulation. Consistently, it was found that endogenous p107 interacts with PP2A/B55α holoenzymes in RCS cells and that this interaction is transiently enhanced via treatment with FGF1 without an increase in B55α protein expression. Moreover, reciprocal proteomic analyses in these cells showed that B55α, and to a lesser extent B55δ, is found in p107 complexes in addition to PP2A/C and PP2A/A, but no other B regulatory subunits were detected.[@cit0039] Others used a catalog approach to independently identify B55α as the B subunit targeting p107 upon FGF1 stimulation in RCS cells.[@cit0114] Consistent with these findings, knockdown of B55α delayed p107 dephosphorylation and cell cycle exit in response to FGF1 stimulation, but did not completely block cell cycle exit.[@cit0039] Furthermore, following dephosphorylation, p107 translocates from the cytoplasm to the nucleus, undergoes changes in complex formation, including complexes with E2F4 and Cyclin/CDK holoenzymes, and enhanced recruitment to the *MYC* promoter within 1.5 hours of FGF1 treatment.[@cit0039] The other pocket proteins, p130 and pRB, are not activated until several hours later, indicating that they do not play an initiating role in chondrocyte maturation or cell cycle exit. Since pRB and p130 are not dephosphorylated until much later after FGF1 treatment, it is more likely that FGF1 differentially mediates activation of pocket proteins in RCS cells via 2 separate pathways, as illustrated in [**Figure 3**](#f0003){ref-type="fig"} and summarized next. Upon treatment with FGF1, p107 is very rapidly activated by PP2A/B55α holoenzymes. This is followed by p107 translocating to the nucleus and binding to the *c-MYC* promoter and most likely to the promoters of other unidentified genes required for chondrocyte maturation and the initiation of cell cycle exit. Meanwhile, pRB and p130 remain inactive due to phosphorylation by CDK4 and CDK2 complexes. The dephosphorylation of pRB and p130 coincides with an increase in p21 expression[@cit0113] several hours later, which cooperate to inactivate Cyclin E/CDK2 complexes. Upregulation of p16 and p27 is also observed after FGF1 treatment,[@cit0101] likely cooperating in the coordinated inactivation of both CDK4 and CDK2 complexes. Differential dephosphorylation of p107 prior to p130 and pRB without the inactivation of CDKs suggests that PP2A/B55α holoenzymes target p107 preferentially over the other pocket proteins. This could be the result of 1) higher affinity for p107, or 2) a consequence of subcellular and/or temporal expression constraints. Differential affinity of PP2A/B55α for p107 over p130 and pRB was already suggested previously.[@cit0082] It is likely that PP2A/B55α participates in the dephosphorylation of p130 and pRB when CDK4 and CDK2 are inactivated by CKIs (5 hours post stimulation). It is also plausible that cooperation by other phosphatases such as PP2A/PR70 and PP1 also takes place at this point. In any case, the pattern of p130 and pRB dephosphorylation and recruitment of p130 to the promoters of E2F dependent genes is consistent with the repression of E2F genes generally observed during cell cycle exit. Figure 3.FGF induces rapid activation of B55α/PP2A holoenzymes, p107 dephosphorylation and activation, and cell cycle exit and maturation in chondrocytes. FGF stimulation through the FGFR3 receptor in chondrocytes leads to increased but transient formation of a B55α-δ/PP2A holoenzyme complexes with p107. This results in a shift on p107 localization from predominantly cytoplasmic to nuclear, formation of complexes with E2F4 and likely other E2Fs, and rapid recruitment to the *c-MYC* promoter, coinciding with its downregulation. p130 remains hyperphosphorylated as CDK4 and CDK2 remain active and may not be actively targeted by B55α/PP2A holoenzymes to switch the equilibrium toward dephosphorylation until CDK activity decreases. p21, p27 and p16 CKI activities increase by different means and appear to trigger inactivation of CDK4 and CDK2 coinciding with p130 and pRB dephosphorylation that occurs 10-15 hours post FGF stimulation. By 24 hrs. chondrocytes have exited the cell cycle and p130 and E2F4 are found at the promoters of cell cycle genes. Because hyperphosphorylated p107 is only detected in the cytoplasmic cellular fractions and this form is rapidly downregulated in the cytoplasm concomitantly with appearance of hypophosphorylated p107 in the nucleus upon FGF stimulation, it seems likely that this dephosphorylation occurs in the cytoplasm. Whether the same is true for p130 is less clear. p130 levels are very low in the absence of FGF stimulation and do not accumulate in the nucleus until several hours post-FGF treatment. While p130 phosphorylation by CDKs is likely occurring in the nucleus, the dephosphorylation step could conceivably occur either in the nucleus or the cytoplasm, hence the question marks for the PP2A reactions and the shuttling of phosphorylated p130 into the cytoplasm.[@cit0039] See text for additional details.

Insights into the potential mechanism of p107/PP2A/B55α complex formation {#s0004-0002}
-------------------------------------------------------------------------

While it is established that the PP2A/B55α holoenzyme is responsible for the dephosphorylation of p107 in RCS cells in response to FGF signaling, the mechanism by which the signal leads to the recruitment of PP2A to p107 is still unclear. It has been suggested that one aspect of this mechanism is the dephosphorylation of the B55α subunit upon treatment with FGF1. Evidence of serine phosphorylation regulating B55α holoenzyme assembly as a possible mechanism to inactivate the holoenzyme in mitosis has been reported in the past.[@cit0115] Kolupaeva et al. have shown through immunoprecipitation of B55α in separate assays that dephosphorylation of B55α, probably on one or more serine residues, occurs around one hour and more clearly at 2 hours after FGF1 treatment, which led to their suggestion that B55α dephosphorylation may activate PP2A to target p107. Using B55α phosphosmimetic mutants, these authors also showed that serine phosphorylation inhibits the binding of the PP2A scaffold subunit and in some cases p107 as well.[@cit0114] This is not fully consistent with the observation that p107 is dephosphorylated and forms complexes with E2F4 as early as 15-30 minutes post treatment.[@cit0039] While dephosphorylation may contribute to the stability of the complex, it is more likely the activation event that recruits PP2A/B55α to p107 occurs within minutes rather than hours after FGF1 signaling.

It is known that in RCS cells, treatment with FGF1 activates MAPK pathways. Indeed, ERK 1/2 and p38 are activated very rapidly- within 5 minutes post treatment with FGF1. Treatment with a MEK1/2 inhibitor, which is directly upstream of ERK in this pathway, inhibits the dephosphorylation of p107 one hour after treatment with FGF,[@cit0109] similar to the knockdown of B55α. This indicates ERK1/2 signaling somehow plays a role in the dephosphorylation of p107 and perhaps the immediate recruitment of the B55α holoenzyme to p107. Also of note, B55α and B55δ holoenzymes dephosphorylate the inhibitory phosphorylation pS259 on Raf1 and pS392 on KSR1,[@cit0093] which are immediately upstream of MEK1/2 in the activation of the MAPK cascade,[@cit0116] and these effects are observed within 5-15 minutes of treatment with EGF or PDGF in NIH-3T3 cells. Thus, activation of the MAPK pathway and p107 all involve B55α and seem to occur in a very narrow time scale, which suggest coordination.

Composition of p107 complexes in RCS cells {#s0004-0003}
------------------------------------------

The composition of p107 complexes has been characterized via mass spectrometric analysis using RCS cell lines stably expressing Flag-tagged p107 at levels that do not preclude their proliferation, nor affect FGF1 induced growth arrest.[@cit0039] In addition to identification of the components of the B55α and B55δ holoenzymes, the presence of several expected binding partners of p107, broadly classified as E2F/DP proteins, DREAM subunits and Cyclin/CDKs complexes, as well as some potential novel interactors was confirmed. Of note, several E2Fs were detected, including not only the repressor E2Fs and components of the DREAM complex, E2F4 and E2F5, but also the activator E2Fs, E2F1 and E2F3. This suggest that p107 not only forms repressor E2F complexes and or DREAM complexes that are recruited to the nucleus, but also targets activator E2Fs, perhaps to rapidly turn them off in response to FGF signaling. Detection of these p107/activator E2F complexes is consistent with previous identification of endogenous p107/E2F1 and p130/E2F1 complexes in human cells.[@cit0037] One expected but interesting group of proteins detected were members of the DREAM complex, an evolutionarily conserved protein complex that serves as both a transcriptional regulator and repressor at different phases of the cell cycle (reviewed in ref.[@cit0117]). The mammalian DREAM complex is composed of DP1 or DP2, p107 or p130 (but not pRB), E2F4 or E2F5 and the MuvB core, which contains Lin 9, Lin 37, Lin 52, Lin 54, and RBBP4[@cit0118] (except DP2, all these proteins are detected in the p107/DREAM complex in chondrocytes). The MuvB core can also form complexes with B-Myb and FoxM1, referred to as B-Myb-MuvB.[@cit0120] The major role of the p130-containing DREAM complex is to repress genes for cell cycle exit and quiescence, while the B-Myb-MuvB complex is recruited in S phase to the promoters of G2/M genes to serve as a transcriptional activator. The "switch" from B-Myb binding to DREAM binding of the MuvB core is the result of phosphorylation of Lin 52 by the DYRK1 kinase (reviewed in refs.[@cit0117]). Consistent with these findings, a very recent publication has implicated the DREAM complex in the regulation of chondrocyte proliferation.[@cit0122] In this study, mice that homozygously express p107 with mutations in the LXCXE binding cleft that render it incapable of binding the MuvB core were crossed with p130 null mice. In MEFs derived from these mice, the DREAM complex failed to assemble, DREAM target genes failed to be repressed, resulting in their increased expression during cell proliferation. Importantly, these mice exhibited neonatal lethality, but were found to be alive at embryonic day 18.5, shortly before birth, which is highly reminiscent of p107/p130 knockout mice.[@cit0102] When the bones of these mice were analyzed, they were found to have abnormally smaller and underdeveloped endocranial bones that the wild type mice, as well as significantly shorter long bones. This overall demonstrates that similar to p107/p130 null mice, mice deficient in DREAM complex assembly display defective chondrocyte proliferative control and endochondral ossification.[@cit0122] Further analysis of the dynamics of these complexes in response to FGF signaling is needed to determine if the MuvB core is found with p107 at the *c-MYC* promoter or other genes whose downregulation is required for maturation and cell cycle exit shortly after treatment with FGF1 in RCS cells. Alternatively, p107 may also promote expression of maturation genes via co-recruitment of other factors yet to be determined upon p107 activation.

Closing Remarks: The CDK/PP2A Equilibrium that Determines the Phosphorylation State of Pocket Proteins Integrates Growth Arrest Signals Through both Inhibition of CDKs and Activation of PP2A {#s0005}
==============================================================================================================================================================================================

Pocket proteins are targeted by PP2A in 2 manners- in an equilibrium with CDKs throughout the cell cycle, which implies a basal PP2A activity, and inducibly upon extracellular signals or stresses. Throughout the cell cycle, phosphorylation and dephosphorylation of pocket proteins is modulated by Cyclin/CDK complexes and PP2A. When cells are treated with inhibitors that affect the synthesis of unstable Cyclins or CDK activity, all 3 pocket proteins are immediately dephosphorylated.[@cit0052] In this regard, signals that result in cell cycle arrest or exit that function through the accumulation of CKIs are time-limited by the rate of accumulation of CKIs that are needed to inhibit CDKs. In this scenario, reduction in CDK activity will need a substantial accumulation of CKIs to shift the equilibrium toward pocket protein dephosphorylation by PP2A. This requires protein synthesis and/or stabilization, which are not extremely fast processes. In contrast, recruitment of PP2A holoenzymes upon extracellular signaling or stresses serves as an alternative mechanism of rapidly targeting pocket proteins. For example, FGF1 signaling promotes the rapid dephosphorylation of p107 as a result of complex formation between p107 and PP2A/B55α holoenzymes, and this happens in the presence of CDK activity that maintains the phosphorylation of pRB and p130. Shifts in the PP2A/CDK balance due to the selective recruitment of PP2A to pocket proteins in response to a variety of signaling cues could serve as a general mechanism for rapid activation of pocket proteins. As described earlier, at least 2 other instances of pocket proteins being rapidly activated as the result of stresses are known. UV irradiation results in the dephosphorylation of p107 within 90 minutes, which also results in a G1 cell cycle arrest.[@cit0051] Oxidative stress also results in the rapid dephosphorylation of all 3 pocket proteins within 30 minutes, and Cyclin/CDK activity is unaffected.[@cit0048] pRB is targeted by PR70 in this context, and it is likely that also targets p107 and p130 given that the kinetics of dephosphorylation matches that of pRB,[@cit0089] and that it has been shown that PR70 also associates with p130.[@cit0082] Moreover, PP2A has also been shown to mediate the localization of pRB on chromatin is response to DNA damage, although the B subunit implicated is unknown.[@cit0123]

It is also important to note that the PP2A activity targeting pocket proteins through the cell cycle is also likely regulated, at least the PP2A activity share mediated by PP2A/B55α and B55δ holoenzymes. The activity of these 2 holoenzymes is required for exit from mitosis, but it is inhibited during mitosis itself (reviewed in refs.[@cit0054]). This is a result of activation of the Gwl kinase by CDK1, which in turn activates ENSA and ARPP19, which directly inhibit PP2A. Thus, it is very likely that the upregulation of PP2A/B55α and B55δ holoenzymes as cells exit mitosis contributes to the rapid dephosphorylation of the 3 pocket proteins prior to entry into G1. In the case of pRB, PP1 also contributes at this cell cycle stage.

Further insights in the mechanism of activation of PP2A through the B-regulatory subunits that target pocket proteins will help uncover new signals with the ability to rapidly halt the cell cycle. Abrupt dephosphorylation of pocket proteins in response to FGF signaling or oxidative stress are likely paradigms for rapid activation of pocket proteins by other unrelated signals.
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